Galmed pharmaceuticals ltd. files annual report on form 20-f for the fiscal year ended december 31, 2023

Tel aviv, israel , april 4, 2024 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its annual report on form 20-f for the fiscal year ended december 31, 2023, with the u.s. securities and exchange commission (the "sec").
GLMD Ratings Summary
GLMD Quant Ranking